Cargando…

A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology

Ovarian low-grade serous carcinoma (LGSC) and high-grade serous carcinoma have distinct molecular profiles, clinical behaviors, and treatment responses. The survival advantage for patients with low-grade carcinoma compared with patients with high-grade histology remains controversial. We retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ming, Jin, Ying, Bi, Yalan, Yin, Jie, Wang, Yongxue, Pan, Lingya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206388/
https://www.ncbi.nlm.nih.gov/pubmed/25342912
http://dx.doi.org/10.2147/OTT.S67812
_version_ 1782340814553219072
author Chen, Ming
Jin, Ying
Bi, Yalan
Yin, Jie
Wang, Yongxue
Pan, Lingya
author_facet Chen, Ming
Jin, Ying
Bi, Yalan
Yin, Jie
Wang, Yongxue
Pan, Lingya
author_sort Chen, Ming
collection PubMed
description Ovarian low-grade serous carcinoma (LGSC) and high-grade serous carcinoma have distinct molecular profiles, clinical behaviors, and treatment responses. The survival advantage for patients with low-grade carcinoma compared with patients with high-grade histology remains controversial. We retrospectively reviewed the medical charts of 381 patients with ovarian serous carcinoma at Peking Union Medical College Hospital from 2007 to 2010. Patients were classified into two groups according to MD Anderson two-tier system: 35 (9.2%) cases with LGSC and 346 with high-grade serous carcinoma. Patients with low-grade serous ovarian cancer had a significantly younger age at diagnosis (46 versus 56 years, P=0.046), and their median progression-free survival (PFS) and overall survival values were 35.0 and 54.0 months, respectively. A multivariate analysis showed that, for serous ovarian cancer, the histological grade was a significant prognostic factor for PFS but not for overall survival (P=0.022 and P=0.0566, respectively). When stratified by the existence of a residual disease, patients with low-grade disease who underwent cytoreductive surgery without macroscopic residual disease (>1 cm) had a significantly improved median PFS time (36.0 months) compared with that of patients with high-grade carcinoma who received optimal cytoreductive surgery (16.0 months, P=0.017). Conversely, patients with low-grade and high-grade carcinoma who were left with macroscopic residue (>1 cm) experienced a similarly shorter median PFS (10.0 and 13.0 months, respectively, P=0.871). The International Federation of Gynecology and Obstetrics stage and residual disease were significant prognostic factors of low-grade carcinoma, while positive ascites was associated with a worse PFS value. Our data showed that LGSC is a different entity from high-grade carcinoma and that LGSC was associated with improved PFS after optimal cytoreductive surgery but not suboptimal operation.
format Online
Article
Text
id pubmed-4206388
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-42063882014-10-23 A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology Chen, Ming Jin, Ying Bi, Yalan Yin, Jie Wang, Yongxue Pan, Lingya Onco Targets Ther Original Research Ovarian low-grade serous carcinoma (LGSC) and high-grade serous carcinoma have distinct molecular profiles, clinical behaviors, and treatment responses. The survival advantage for patients with low-grade carcinoma compared with patients with high-grade histology remains controversial. We retrospectively reviewed the medical charts of 381 patients with ovarian serous carcinoma at Peking Union Medical College Hospital from 2007 to 2010. Patients were classified into two groups according to MD Anderson two-tier system: 35 (9.2%) cases with LGSC and 346 with high-grade serous carcinoma. Patients with low-grade serous ovarian cancer had a significantly younger age at diagnosis (46 versus 56 years, P=0.046), and their median progression-free survival (PFS) and overall survival values were 35.0 and 54.0 months, respectively. A multivariate analysis showed that, for serous ovarian cancer, the histological grade was a significant prognostic factor for PFS but not for overall survival (P=0.022 and P=0.0566, respectively). When stratified by the existence of a residual disease, patients with low-grade disease who underwent cytoreductive surgery without macroscopic residual disease (>1 cm) had a significantly improved median PFS time (36.0 months) compared with that of patients with high-grade carcinoma who received optimal cytoreductive surgery (16.0 months, P=0.017). Conversely, patients with low-grade and high-grade carcinoma who were left with macroscopic residue (>1 cm) experienced a similarly shorter median PFS (10.0 and 13.0 months, respectively, P=0.871). The International Federation of Gynecology and Obstetrics stage and residual disease were significant prognostic factors of low-grade carcinoma, while positive ascites was associated with a worse PFS value. Our data showed that LGSC is a different entity from high-grade carcinoma and that LGSC was associated with improved PFS after optimal cytoreductive surgery but not suboptimal operation. Dove Medical Press 2014-10-16 /pmc/articles/PMC4206388/ /pubmed/25342912 http://dx.doi.org/10.2147/OTT.S67812 Text en © 2014 Chen et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Chen, Ming
Jin, Ying
Bi, Yalan
Yin, Jie
Wang, Yongxue
Pan, Lingya
A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology
title A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology
title_full A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology
title_fullStr A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology
title_full_unstemmed A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology
title_short A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology
title_sort survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206388/
https://www.ncbi.nlm.nih.gov/pubmed/25342912
http://dx.doi.org/10.2147/OTT.S67812
work_keys_str_mv AT chenming asurvivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology
AT jinying asurvivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology
AT biyalan asurvivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology
AT yinjie asurvivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology
AT wangyongxue asurvivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology
AT panlingya asurvivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology
AT chenming survivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology
AT jinying survivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology
AT biyalan survivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology
AT yinjie survivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology
AT wangyongxue survivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology
AT panlingya survivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology